Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04841369
Other study ID # CS-CTP-PCV-III
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 13, 2021
Est. completion date September 20, 2022

Study information

Verified date October 2022
Source CanSino Biologics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years several years is approximately 60% in Western countries.This is a single center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3 months,compared to PCV13.


Recruitment information / eligibility

Status Completed
Enrollment 3420
Est. completion date September 20, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks and older
Eligibility Inclusion Criteria: - Healthy subjects of 2 months (minimum 6 weeks), 3 months , 7 months and above; - Willing to provide proof of identity; - Without vaccination history of pneumococcal vaccine; - None-pregnancy or do not plan to pregnancy recently;; - Volunteers of 18 years old and above who have the ability to understand clinical studie progress and sign informed consent; - Volunteers of 8-17 years old and their guardians who willing sign informed consent; - Able to understand and sign the informed consent by their guardians or trustees for the volunteers of 8 years old and below; - Able and willing comply with the requirements of the protocol Exclusion Criteria: - Volunteers whose axillary body temperature was >37.0# before vaccination - Volunteers who suffered from Congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc; - Volunteers who has a history of epilepsy, convulsions or psychosis; - Allergic person; - Any prior administration of blood products in last 3 month; - Any prior administration of other research medicines in last 1 month; - Plans to participate in or is participating in any other drug clinical study; - Any prior administration of attenuated live vaccine in last 14 days; - Any prior administration of subunit or inactivated vaccines in last 7 days; - Had fever before vaccination, Volunteers with temperature >37.0°C on axillary setting; - According to the investigator's judgement, the subjects have any other factors that make them unfit to enroll the clinical trial

Study Design


Intervention

Biological:
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
0.5mL,Intramuscular
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
0.5mL,Intramuscular

Locations

Country Name City State
China Neihuang Center for Disease Control and Prevention Anyang Henan

Sponsors (2)

Lead Sponsor Collaborator
CanSino Biologics Inc. Henan Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of PCV13i in preventing pneumococcal infections Occurance of adverse reactions in all subjects Within 7 days post each vaccination
Primary Safety of PCV13i in preventing pneumococcal infections Occurance of adverse reactions in all subjects Within 30 days post each vaccination
Primary Immunogenicity of PCV13i in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B) Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml 30 days post three doses
Primary Immunogenicity of PCV13i in subjects of 7 to 11 months old (Arm 4A-4B) Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml 30 days post three doses
Primary Immunogenicity of PCV13i in subjects of 12 months to 5 years old (Arm 5A, 5B, 6A, 6B) Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml 30 days post last dose of vaccination
Primary Immunogenicity of PCV13i in subjects of age 50 years old and above (Arm 6A, 6B, 7A, 7B) Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml 30 days post vaccination
Secondary Immuogenicity in terms of GMT in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B) GMT of serotype-specific OPA antibody with the titer of =1:8 ratio 30 days post three doses
Secondary Immunogenicity in terms of IgG concentration in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B) Serotype-specific Immunoglobulin G with a concentration of =1.0µg/ml 30 days post three doses
Secondary Safety of PCV13i in terms of in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B) Occurance of SAE in subjects of this age group 6 months post one to three doses of vaccination
Secondary Immuogenicity in terms of GMT in subjects of 7 to 11 months old (Arm 3A-3B) GMT of serotype-specific OPA antibody with the titer of =1:8 ratio 30 days post two doses
Secondary Immuogenicity in terms of GMT in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B) GMT of serotype-specific OPA antibody with the titer of =1:8 ratio 30 days post last dose of vaccination
Secondary Immunogenicity in terms of IgG concentration in subjects of 7 to 11 months old (Arm 3A-3B) Serotype-specific Immunoglobulin G with a concentration of =1.0µg/ml 30 days post two doses
Secondary Immunogenicity in terms of IgG concentration in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B) Serotype-specific Immunoglobulin G with a concentration of =1.0µg/ml 30 days post last dose of vaccination
Secondary Safety of PCV13i in terms of SAE in subjects of 7 to 11 months old (Arm 3A-3B) Occurance of SAE in subjects of this age group 6 months post two doses
Secondary Safety of PCV13i in terms of SAE in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B) Occurance of SAE in subjects of this age group 6 months post last dose of vaccination
See also
  Status Clinical Trial Phase
Completed NCT03726216 - Xydalba Utilization Registry in France
Completed NCT03605498 - OR PathTrac (Tracking Intra-operative Bacterial Transmission)
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Recruiting NCT02074865 - Children's Antibiotic Resistant Infections in Low Income Countries N/A
Completed NCT01932034 - Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software N/A
Completed NCT01689207 - To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Phase 1
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Completed NCT00983255 - Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) Phase 1
Completed NCT00799591 - French Study In ICU Patients Treated With Tigecycline N/A
Completed NCT00678106 - Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections Phase 1
Completed NCT00478855 - Tazocin Intervention Study Phase 4
Completed NCT01074775 - Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection N/A
Terminated NCT00431028 - Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery Phase 1/Phase 2
Not yet recruiting NCT03634904 - Serum Ceftazidime Concentrations in Hemodialysis Patients N/A
Recruiting NCT05684705 - Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 Phase 1
Recruiting NCT03858387 - PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Enrolling by invitation NCT04764058 - Efficacy and Safety of Colistin Based Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2